Government Price Setting
What Is Government Price Setting?

The federal government and several states have passed legislation that would establish an upper payment limit or maximum fair price for certain drugs. These laws limit how much a health plan reimburses an infusion provider for a particular drug regardless of the drug’s acquisition or administration cost.
States across the United States are exploring enacting laws that would implement Prescription Drug Affordability Boards (PDABs). The role of these boards is to identify medications believed to have affordability challenges for patients. Once the drugs are identified, most states authorize the PDAB to establish an upper payment limit (UPL), or a ceiling for how much any state-regulated plan will reimburse for the selected drug.
The federal government has implemented a similar mechanism known as “maximum fair price” for selected drugs. The federal government’s implementation of this policy has been staggered across a number of years. NICA is concerned with how these policies will impact reimbursement for infusion providers. Through our advocacy efforts, we have asked state and federal legislators to reconsider these policies or establish protections for infusion providers.
To learn more about the Medicare Drug Price Negotiation Program, how it could affect infusion providers, and how the Protecting Patient Access to Cancer and Complex Therapies Act would address the issue, click below.
How Government Payment Limits Affect Infusion Centers and Patients
Government price setting policies, such as Upper Payment Limits (UPLs) established by Prescription Drug Affordability Boards (PDABs), can have real-world consequences for infusion providers and the patients they serve. The infographic below illustrates how upper payment limits may reduce reimbursement for infusion centers, sometimes below the cost of acquiring and administering a medication, while offering little to no affordability relief for patients. When infusion providers cannot sustain these losses, patient access to provider-administered therapies may be delayed, disrupted, or eliminated altogether.

Download a printable resource outlining how PDABs and Upper Payment Limits affect infusion center sustainability and patient access.
Government Price Setting Legislative Map
As states explore policies to reduce prescription drug costs, some have established Prescription Drug Affordability Boards (PDABs) with the authority to evaluate medication affordability and, in certain cases, impose upper payment limits (UPLs). While these policies are intended to address rising drug costs, limits on reimbursement for provider-administered medications can create financial challenges for infusion centers, particularly when reimbursement does not adequately cover medication acquisition and administration costs. This legislative map was created to help infusion centers, nurses, and healthcare professionals understand the state laws governing PDABs and UPLs, including board authority, reimbursement restrictions, and applicable requirements. Use this information to monitor policies that may affect infusion center operations, understand potential reimbursement implications, or contact lawmakers to advocate for protections that preserve patient access to community-based infusion care.
Click on a state to view applicable government price setting laws, including PDAB authority and upper payment limit provisions.
One thing to keep in mind: Not all states with PDABs have authorized or implemented upper payment limits, and the scope of these policies varies significantly. Depending on the state, payment restrictions may apply to certain medications, health plans, or purchasers. Providers should review each state's requirements to understand how current or proposed policies may affect reimbursement and patient access to care. State-level policies are also distinct from federal programs, such as the Medicare Drug Price Negotiation Program. To support Medicare negotation reforms, contact your federal legislators in support of the Protecting Patient Access to Cancer and Complex Therapies Act (PACTA).
Government Price Setting Action Campaign
Take action against government price setting, including Prescription Drug Affordability Boards and upper payment limits, by asking your elected officials to protect infusion center reimbursement.